Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

This study has been completed.
Sponsor:
Information provided by:
CTI BioPharma
ClinicalTrials.gov Identifier:
NCT00106600
First received: March 28, 2005
Last updated: August 21, 2007
Last verified: August 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: March 2007
  Estimated Primary Completion Date: No date given